Kh176    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
21Mitochondrial disease4

21. Mitochondrial disease    [ 23 clinical trials,   29 drugs,   (DrugBank: 28 drugs),   44 drug target genes,   65 drug target pathways]
Searched query = "Mitochondrial disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 23 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-001696-79-NL
(EUCTR)
06/09/201618/08/2016A Phase II study with KH176 in patients with mitochondrial diseaseA double-blind, randomized, placebo-controlled, single-center, two-way cross-over study with KH176 in patients with the mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation and clinical signs of mitochondrial disease - The KHENERGY study Inherited mitochondrial disease, including MELAS (mitochondrial Encephalopathy Lactic Acidosis and Stroke like episodes) and MIDD (Maternally Inherited Diabetes and Deafness);Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]Product Name: KH176
Product Code: KH176
Khondrion BVNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Netherlands
2NCT02909400
(ClinicalTrials.gov)
September 201613/9/2016The KHENERGY StudyAn Exploratory, Double-blind, Randomized, Placebo-controlled, Single-center, Two-way Cross-over Study With KH176 in Patients With the Mitochondrial DNA tRNALeu(UUR) m.3243A>G Mutation and Clinical Signs of Mitochondrial DiseaseMitochondrial Diseases;Mitochondrial Myopathies;Mitochondrial Encephalomyopathies;MELAS;MIDDDrug: KH176;Drug: placeboKhondrion BVRadboud UniversityCompleted18 YearsN/AAll20Phase 2Netherlands
3NCT02544217
(ClinicalTrials.gov)
May 201519/4/2015A Dose-escalating Clinical Trial With KH176A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Clinical Trial With KH176MELAS;LHON;Leigh Syndrome;Mitochondrial Disease;Mitochondrial DNA tRNALeu(UUR) m.3243ADrug: KH176;Drug: placeboKhondrion BVDrug Research Unit Ghent, BelgiumCompleted18 Years55 YearsMale32Phase 1Belgium
4EUCTR2020-003124-16-NL
(EUCTR)
20/10/2020The KHENERGYC study: a placebo controlled, double-blind study to explore the safety, efficacy and pharmacokinetics of sonlicromanol in children with a mitochondrial disease.A randomized placebo controlled, double-blind phase II study to explore the safety, efficacy and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease. Genetically confirmed mitochondrial disease;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]Product Name: Sonlicromanol
Product Code: KH176
INN or Proposed INN: sonlicromanol
Other descriptive name: KH176
Khondrion B.V.NULLNAFemale: yes
Male: yes
24Phase 2Netherlands